Hyaluronan modulates TRPV1 channel opening, reducing peripheral nociceptor activity and pain

Nature Communications

Volumn 6, Issue , 2015, Pages

  Caires, Rebeca ^a   Luis, Enoch ^a   Taberner, Francisco J ^a   Fernandez Ballester, Gregorio ^a   Ferrer Montiel, Antonio ^a   Balazs, Endre A ^b   Gomis, Ana ^a   Belmonte, Carlos ^a   De La Peña, Elvira ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Matrix Biology Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CAPSAICIN; HYALURONIC ACID; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; VANILLOID RECEPTOR 1; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; CALCIUM; IMMUNOLOGICAL ADJUVANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPA1 PROTEIN, MOUSE; TRPM8 PROTEIN, MOUSE; TRPV1 PROTEIN, HUMAN; TRPV1 PROTEIN, MOUSE; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR; VASODILATOR AGENT;

BODY TEMPERATURE; METABOLISM; NERVOUS SYSTEM; NEUROLOGY; PEPTIDE; PH; POLYSACCHARIDE; RODENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEAT; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NONHUMAN; PAIN; PAIN RECEPTOR; PH; RAT; SENSORY NERVE; SPINAL GANGLION; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHO CELL LINE; CRICETULUS; CYTOLOGY; DRUG EFFECTS; ELECTRON MICROSCOPY; INNERVATION; KNOCKOUT MOUSE; METABOLISM; MOLECULAR MODEL; NERVE CELL; NOCICEPTIVE PAIN; PATCH CLAMP TECHNIQUE; SITE DIRECTED MUTAGENESIS; STIFLE; TUMOR CELL LINE; WISTAR RAT;

MUS; RATTUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BEHAVIOR, ANIMAL; BRADYKININ; CALCIUM; CAPSAICIN; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; GANGLIA, SPINAL; HEK293 CELLS; HOT TEMPERATURE; HUMANS; HYALURONIC ACID; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NEURONS; NOCICEPTIVE PAIN; NOCICEPTORS; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; SENSORY SYSTEM AGENTS; STIFLE; TRANSIENT RECEPTOR POTENTIAL CHANNELS; TRPM CATION CHANNELS; TRPV CATION CHANNELS; VASODILATOR AGENTS;

EID: 84940481816     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9095     Document Type: Article

References (68)

1. Fraser, J. R., Laurent, T. C. & Laurent, U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242, 27-33 (1997).
2. Dicker, K. T. et al. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater. 10, 1558-1570 (2014).
3. Balazs, E. A. The viscoelastic intercellular matrix and control of cell function by hyaluronan. in The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. (ed. Laurent, T. C.) 185-204 (Portland Press, 1998).
4. Evanko, S. P., Tammi, M. I., Tammi, R. H. & Wight, T. N. Hyaluronandependent pericellular matrix. Adv. Drug Deliv. Rev. 59, 1351-1365 (2007).
5. Scheibner, K. A. et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177, 1272-1281 (2006).
6. Garg, H. G. & Hales, C. A. Chemistry and Biology of Hyaluronan 1st edition (Elsevier, 2004).
7. De la Peña, E., Sala, S., Rovira, J. C., Schmidt, R. F. & Belmonte, C. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain 99, 501-508 (2002).
8. Kochlamazashvili, G. et al. The extracellular matrix molecule hyaluronic acid regulates hippocampal synaptic plasticity by modulating postsynaptic L-type Ca(2+) channels. Neuron 67, 116-128 (2010).
9. Pozo, M. A., Balazs, E. A. & Belmonte, C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp. Brain Res. 116, 3-9 (1997).
10. Gomis, A., Pawlak, M., Balazs, E. A., Schmidt, R. F. & Belmonte, C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 50, 314-326 (2004).
11. Gomis, A., Miralles, A., Schmidt, R. F. & Belmonte, C. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan application. Pain 130, 126-136 (2007).
12. Balazs, E. A. in Disorders of the Knee (ed. Helfet, A.) 61-74 (J.B. Lippincott, 1982).
13. Balazs, E. A. & Denlinger, J. L. Clinical uses of hyaluronan. Ciba Found. Symp. 143, 265-275 discussion 275-280, 281-265 (1989).
14. Sampson, P. M., Rochester, C. L., Freundlich, B. & Elias, J. A. Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production. Evidence for cytokine-regulated hyaluronan (hyaluronic acid) degradation and human lung fibroblast-derived hyaluronidase. J. Clin. Invest. 90, 1492-1503 (1992).
15. Natura, G. et al. Neuronal prostaglandin E2 receptor subtype EP3 mediates antinociception during inflammation. Proc. Natl Acad. Sci. USA 110, 13648-13653 (2013).
16. Bert, J. M. & Waddell, D. D. Viscosupplementation with hylan g-f 20 in patients with osteoarthrosis of the knee. Ther. Adv. Musculoskelet. Dis. 2, 127-132 (2010).
17. Chevalier, X. et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann. Rheum. Dis. 69, 113-119 (2010).
18. Ayhan, E., Kesmezacar, H. & Akgun, I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J. Orthop. 5, 351-361 (2014).
19. Gingerich, D. A., Auer, J. A. & Fackelman, G. E. Effect of exogenous hyaluronic acid on joint function in experimentally induced equine osteoarthritis: dosage titration studies. Res. Vet. Sci. 30, 192-197 (1981).
20. Caterina, M. J. et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824 (1997).
21. Gauldie, S. D., McQueen, D. S., Pertwee, R. & Chessell, I. P. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol. 132, 617-621 (2001).
22. Szabo, A. et al. Role of transient receptor potential vanilloid 1 receptors in adjuvant-induced chronic arthritis: in vivo study using gene-deficient mice. J. Pharmacol. Exp. Ther. 314, 111-119 (2005).
23. Huang, J., Zhang, X. & McNaughton, P. A. Inflammatory pain: the cellular basis of heat hyperalgesia. Curr. Neuropharmacol. 4, 197-206 (2006).
24. Honore, P. et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)- urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J. Pharmacol. Exp. Ther. 314, 410-421 (2005).
25. Reilly, R. M. et al. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. J. Pharmacol. Exp. Ther. 342, 416-428 (2012).
26. Voets, T. et al. The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. Nature 430, 748-754 (2004).
27. 2+-activated cation channel TRPM4 is regulated by phosphatidylinositol 4,5-biphosphate. EMBO J. 25, 467-478 (2006).
28. Studer, M. & McNaughton, P. A. Modulation of single-channel properties of TRPV1 by phosphorylation. J. Physiol. 588, 3743-3756 (2010).
29. Julius, D. TRP channels and pain. Annu. Rev. Cell Dev. Biol. 29, 355-384 (2013).
30. Cesare, P. & McNaughton, P. A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc. Natl Acad. Sci. USA 93, 15435-15439 (1996).
31. Fernihough, J., Gentry, C., Bevan, S. & Winter, J. Regulation of calcitonin generelated peptide and TRPV1 in a rat model of osteoarthritis. Neurosci. Lett. 388, 75-80 (2005).
32. Story, G. M. et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112, 819-829 (2003).
33. Bautista, D. M. et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 448, 204-208 (2007).
34. Fajardo, O., Meseguer, V., Belmonte, C. & Viana, F. TRPA1 channels mediate cold temperature sensing in mammalian vagal sensory neurons: pharmacological and genetic evidence. J. Neurosci. 28, 7863-7875 (2008).
35. Bost, F., Diarra-Mehrpour, M. & Martin, J. P. Inter-alpha-trypsin inhibitor proteoglycan family - A group of proteins binding and stabilizing the extracellular matrix. Eur. J. Biochem. 252, 339-346 (1998).
36. Yang, B., Yang, B. L., Savani, R. C. & Turley, E. A. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J. 13, 286-296 (1994).
37. Banerji, S. et al. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat. Struct. Mol. Biol. 14, 234-239 (2007).
38. Klionsky, L. et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J. Pharmacol. Exp. Ther. 319, 192-198 (2006).
39. Naylor, J. & Beech, D. J. Extracellular ion channel inhibitor antibodies. Open Drug Discov. J. 1, 36-42 (2009).
40. Cao, E., Liao, M., Cheng, Y. & Julius, D. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504, 113-118 (2013).
41. Lainez, S. et al. GABAA receptor associated protein (GABARAP) modulates TRPV1 expression and channel function and desensitization. FASEB J. 24, 1958-1970 (2010).
42. Engler, A. et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem. Biophys. Res. Commun. 359, 884-888 (2007).
43. Menigoz, A. & Boudes, M. The expression pattern of TRPV1 in brain. J. Neurosci. 31, 13025-13027 (2011).
44. Bevan, S., Quallo, T. & Andersson, D. A. Trpv1. Handb. Exp. Pharmacol. 222, 207-245 (2014).
45. Fernandes, E. S., Fernandes, M. A. & Keeble, J. E. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br. J. Pharmacol. 166, 510-521 (2012).
46. Zhang, W. et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18, 476-499 (2010).
47. Valdes, A. M. et al. The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann. Rheum. Dis. 70, 1556-1561 (2011).
48. Schaible, H. G., Ebersberger, A. & Von Banchet, G. S. Mechanisms of pain in arthritis. Ann. NY Acad. Sci. 966, 343-354 (2002).
49. Cho, W. G. & Valtschanoff, J. G. Vanilloid receptor TRPV1-positive sensory afferents in the mouse ankle and knee joints. Brain Res. 1219, 59-65 (2008).
50. Kelly, S. et al. Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain. Ann. Rheum. Dis. 74, 252-259 (2013).
51. Balazs, E. A. Viscoelastic properties of hyaluronan acid and its therapeutic use. In: Chemistry and Biology of Hyaluronan. (eds Grag, H. G. & Hales, C. A.) 415-455 (Elsevier, 2004).
52. Gavenis, K. et al. Expression of ion channels of the TRP family in articular chondrocytes from osteoarthritic patients: changes between native and in vitro propagated chondrocytes. Mol. Cell. Biochem. 321, 135-143 (2009).
53. Dityatev, A., Schachner, M. & Sonderegger, P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat. Rev. Neurosci. 11, 735-746 (2010).
54. Hylin, M. J., Orsi, S. A., Moore, A. N. & Dash, P. K. Disruption of the perineuronal net in the hippocampus or medial prefrontal cortex impairs fear conditioning. Learn. Mem. 20, 267-273 (2013).
55. Martins, D., Tavares, I. & Morgado, C. 'Hotheaded': the role OF TRPV1 in brain functions. Neuropharmacology 85, 151-157 (2014).
56. Edwards, J. G. TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications. Prog. Drug Res. 68, 77-104 (2014).
57. Gonzalez-Reyes, L. E., Ladas, T. P., Chiang, C. C. & Durand, D. M. TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo. Exp. Neurol. 250, 321-332 (2013).
58. Mori, F. et al. TRPV1 channels regulate cortical excitability in humans. J. Neurosci. 32, 873-879 (2012).
59. Viana, F., de la Pena, E., Pecson, B., Schmidt, R. F. & Belmonte, C. Swelling-activated calcium signalling in cultured mouse primary sensory neurons. Eur. J. Neurosci. 13, 722-734 (2001).
60. Cabedo, H., Carteron, C. & Ferrer-Montiel, A. Oligomerization of the sensory and motor neuron-derived factor prevents protein O-glycosylation. J. Biol. Chem. 279, 33623-33629 (2004).
61. Gomis, A. et al. Blockade of nociceptive sensory afferent activity of the rat knee joint by the bradykinin B2 receptor antagonist fasitibant. Osteoarthritis Cartilage 21, 1346-1354 (2013).
62. Schwede, T., Kopp, J., Guex, N. & Peitsch, M. C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385 (2003).
63. Guex, N. & Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723 (1997).
64. Krieger, E., Darden, T., Nabuurs, S. B., Finkelstein, A. & Vriend, G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57, 678-683 (2004).
65. Fernandez-Ballester, G. & Ferrer-Montiel, A. Molecular modeling of the fulllength human TRPV1 channel in closed and desensitized states. J. Membr. Biol. 223, 161-172 (2008).
66. Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477-486 (1996).
67. Schymkowitz, J. et al. The FoldX web server: an online force field. Nucleic Acids Res. 33, W382-W388 (2005).
68. Duan, Y. et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem. 24, 1999-2012 (2003).